Cannabis equities are having a moment few saw coming a year ago. The AdvisorShares Pure US Cannabis ETF (MSOS) touched its highest levels of 2026 this week, with a 103.7% one-year net asset value return that dwarfs both the North American Marijuana Index's 36.9% gain and the S&P 500's 29.8% climb. Money is flowing in ahead of a June 29 DEA administrative hearing on marijuana rescheduling, and Trulieve's landmark listing on the NYSE has given traders a fresh reason to bet on the sector's next leg up.
The rally isn't happening in a vacuum. Multi-state operators have spent years building out compliance infrastructure - seed-to-sale tracking, METRC integration, point-of-sale systems built for an industry that still can't touch federal banking without workarounds - largely because the regulatory ground kept shifting beneath them. That operational discipline matters more now, not less, as companies position for uplisting to senior exchanges. Dispensary operators watching this from the retail floor, whether in Florida or Colorado, know that back-office readiness is what separates a company that can seize a Schedule III window from one that gets caught flat-footed; platforms offering colorado cannabis dispensary pos software have become part of that readiness story, since clean transaction records and inventory logs are exactly what auditors and underwriters want to see when a company applies for a senior listing. colorado cannabis dispensary pos software
Trulieve's Structural Move Sets a Template
Trulieve, MSOS's largest holding at roughly 30% of assets, began trading on the NYSE under the ticker TRLV this week. To get there, the company split its medical cannabis operations from its adult-use business - a structural maneuver that let it qualify for a senior exchange listing despite federal illegality still hanging over most of its revenue base. CEO Kim Rivers framed it as a milestone tied directly to the Trump administration's move to reclassify medical marijuana under Schedule III. Alliance Global points to Trulieve's concentration in medical-only states, including expanding markets like Texas and Georgia, as a distinguishing asset. Other operators are watching closely; a listing like this doesn't just raise a company's profile, it opens doors to institutional capital that's been effectively closed for a decade.
Why the Rescheduling Hearing Carries Real Weight
The June 29 hearing will examine whether broader cannabis products, not just state-licensed medical marijuana, should move to Schedule III. That distinction matters enormously for operators still buried under Section 280E, the tax code provision that bars cannabis businesses from deducting ordinary expenses like payroll and rent because the plant remains a controlled substance. Acting Attorney General Todd Blanche's April action already shifted the ground for medical-only products, eliminating some of that tax exposure. A broader move would touch adult-use operators too - the companies running the bulk of dispensary storefronts across the country. Trump's nomination of Blanche to serve as permanent attorney general has only reinforced investor confidence that the rescheduling track will continue.
What Uplisting Actually Changes for Operators
Here's the catch with all this optimism: rescheduling and uplisting don't automatically fix a balance sheet. What they do is widen the door. AdvisorShares notes the shift could strengthen earnings, free cash flow, and access to banking services and institutional investors - the kind of capital that's been scarce for plant-touching businesses. Cresco Labs' $50 million revolving credit facility from Needham Bank, secured this week, is an early example of what that access can look like in practice. CEO Charlie Bachtell called it a non-dilutive tool for acquisitions and a step toward a future senior listing. Tilray, though not part of MSOS, is signaling similar intent with its at-the-market program proceeds.
- Verano (VRNO) carries the highest analyst upside among MSOS holdings, at roughly 195%
- Jushi Holdings (JUSHF) follows at about 183%, with Cresco Labs (CRLBF) near 99%
- Green Thumb Industries (GTBIF) shows 70% upside, ahead of both Trulieve and Curaleaf among the ETF's largest positions
Retail trader sentiment on platforms like Stocktwits is running hot, with several MSOS holdings tagged "extremely bullish." That enthusiasm is worth noting, but it's not a substitute for fundamentals. Operators still face state-by-state license caps, inconsistent lab testing standards, and compliant packaging rules that vary by jurisdiction. Investors chasing the next uplisting candidate should remember that regulatory momentum and operational execution are two different things - and only one of them shows up in a balance sheet.
